SequelSEC

CONMED Corp CNMD

Electromedical & Electrotherapeutic Apparatus · CIK 0000816956 · Fiscal year ends 1231

Revenue
$1.37B
Fiscal year ended 2025-12-31
Operating income
$102.62M
Fiscal year ended 2025-12-31
Free cash flow
$150.88M
Fiscal year ended 2025-12-31

CONMED Corp (CNMD) reported revenue of $1.37B and net income of $47.06M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from CONMED Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

CONMED Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.37B$1.31B$1.24B$1.05B$1.01B$862.46M$955.10M$859.63M$796.39M$763.52M
Cost of revenue$624.25M$573.98M$568.50M$474.23M$442.60M$402.16M$430.38M$390.52M$365.35M$355.19M
Gross profit$750.48M$733.03M$676.24M$571.24M$568.04M$460.30M$524.72M$469.11M$431.04M$408.33M
Operating income$102.62M$200.33M$120.60M$70.05M$109.72M$46.01M$79.11M$71.30M$46.94M$37.68M
Net income$47.06M$132.42M$64.46M-$80.58M$62.54M$9.52M$28.62M$40.85M$55.49M$14.66M
Research & development$55.88M$54.43M$52.60M$47.15M$43.56M$40.47M$45.46M$42.19M$32.31M$32.25M
Weighted-average diluted sharesshares 31.15Mshares 31.15Mshares 31.55Mshares 30.04Mshares 32.22Mshares 29.46Mshares 29.50Mshares 28.89Mshares 28.17Mshares 27.96M
Pretax income$71.12M$163.03M$80.83M-$70.86M$73.10M$1.60M$31.22M$50.65M$28.73M$19.38M
Income tax expense$24.06M$30.61M$16.37M$9.72M$10.56M-$7.91M$2.60M$9.80M-$26.76M$4.71M
Diluted EPS$1.51$4.25$2.04$-2.68$1.94$0.32$0.97$1.41$1.97$0.52
Selling, general & administrative$591.97M$478.28M$503.04M$454.04M$414.75M$373.82M$400.14M$355.62M$351.80M$338.40M
General & administrative$131.96M$117.46M$111.24M$96.11MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CONMED Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$25.86M$17.51M$32.62M$27.43M
Total assets$2.33B$2.31B$2.30B$2.30B$1.77B$1.75B$1.78B$1.37B$1.36B$1.33B
Current assets$672.86M$640.01M$615.65M$581.23M$460.12M$416.65M$397.36M$374.35M$356.78M$330.51M
Total liabilities$1.29B$1.34B$1.47B$1.55B$980.58M$1.04B$1.06B$706.87M$726.53M$748.41M
Current liabilities$315.04M$278.13M$310.73M$296.55M$196.65M$190.20M$188.09M$160.94M$150.00M$113.95M
Total equity incl. NCI$1.03B$962.68M$834.22M$745.54M$785.44M$709.04M$710.47M$662.27M$631.43M$580.58M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$355.54M$346.72M$318.32M$332.32M$231.64M$194.87M$164.62M$154.60M$141.44M$135.87M
Accounts receivable$247.83M$237.73M$242.28M$191.34M$183.88M$177.15M$189.10M$181.55M$167.04M$148.24M
Goodwill$807.01M$805.36M$806.84M$815.43M$617.53M$618.44M$618.04M$400.44M$401.95M$397.66M
Long-term debt$834.23M$905.07M$973.14M$985.08M$672.41M$735.22M$755.21M$438.56M$471.74M$488.29M
Accounts payable$93.65M$102.25M$88.22M$73.39M$58.20M$53.31M$55.97M$53.50M$42.04M$41.65M

Cash flow

CONMED Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$170.69M$166.97M$125.35M$33.36M$111.77M$64.53M$95.13M$74.70M$65.57M$39.88M
Capital expenditures$19.81M$13.08M$19.03M$21.78M$14.87M$13.01M$20.07M$16.51M$12.84M$14.75M
Investing cash flow-$20.96M-$13.08M-$20.03M-$249.53M-$14.87M-$13.64M-$387.66M-$16.51M-$29.05M-$266.02M
Financing cash flow-$135.82M-$151.00M-$110.43M$225.00M-$101.55M-$52.06M$300.88M-$72.26M-$34.88M$182.54M
Net change in cash$16.36M$163.00K-$4.65M$8.10M-$6.51M$1.50M$8.34M-$15.11M$5.19M-$45.08M
Stock-based compensation$28.32M$25.56M$24.26M$21.73M$16.34M$13.11M$11.78M$10.04M$8.47M$8.38M
Common dividends paid$24.75M$24.65M$24.50M$23.96M$23.26M$22.82M$22.60M$22.44M$22.31M$22.21M
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

CONMED Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$150.88M$153.88M$106.32M$11.58M$96.90M$51.52M$75.07M$58.19M$52.72M$25.13M
Gross margin54.6%56.1%54.3%54.6%56.2%53.4%54.9%54.6%54.1%53.5%
Operating margin7.5%15.3%9.7%6.7%10.9%5.3%8.3%8.3%5.9%4.9%
FCF margin11.0%11.8%8.5%1.1%9.6%6.0%7.9%6.8%6.6%3.3%
SBC / revenue2.1%2.0%1.9%2.1%1.6%1.5%1.2%1.2%1.1%1.1%
Current ratio2.14x2.30x1.98x1.96x2.34x2.19x2.11x2.33x2.38x2.90x
Revenue YoY growth5.2%5.0%19.1%3.4%17.2%-9.7%11.1%7.9%4.3%Unavailable
Net margin3.4%10.1%5.2%-7.7%6.2%1.1%3.0%4.8%7.0%1.9%
R&D / revenue4.1%4.2%4.2%4.5%4.3%4.7%4.8%4.9%4.1%4.2%
CapEx / revenue1.4%1.0%1.5%2.1%1.5%1.5%2.1%1.9%1.6%1.9%
Long-term debt / equity0.81xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate33.8%18.8%20.3%Unavailable14.4%-493.7%8.3%19.3%-93.1%24.3%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CNMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing
10-K · Filed 2025-02-18View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.